Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 10/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17486883 | 0.85 | LMNA (0.76) | LMNASMN1; SMN2POLBADORA2BMAPT | |
| SCHEMBL31482443 | 0.81 | ADORA2B (0.81) | LMNASMN1; SMN2ADORA2BMAPTADORA2A | |
| SCHEMBL4384952 | 0.81 | ADORA2B (0.78) | LMNASMN1; SMN2ADORA2BMAPTADORA2A | |
| SCHEMBL11702145 | 0.80 | ADORA2B (0.78) | LMNASMN1; SMN2ADORA2BMAPTADORA2A | |
| SCHEMBL11701929 | 0.80 | ADORA2B (0.78) | LMNASMN1; SMN2ADORA2BMAPTADORA2A | |
| SCHEMBL11699832 | 0.80 | ADORA2B (0.78) | LMNASMN1; SMN2ADORA2BMAPTADORA2A | |
| SCHEMBL10394216 | 0.80 | ADORA2B (0.78) | LMNASMN1; SMN2ADORA2BMAPTADORA2A | |
| SCHEMBL10063431 | 0.79 | LMNA (0.80) | LMNASMN1; SMN2POLBADORA2BMAPT | |
| Isbufylline SCHEMBL678978 | 0.78 | LMNA (0.78) | LMNASMN1; SMN2POLBADORA2BMAPT | |
| SCHEMBL8443037 | 0.78 | ADORA2B (0.77) | LMNASMN1; SMN2ADORA2BMAPTADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3197458-B1 | DERMOCOSMETIC OR PHARMACEUTICAL USE OF A COMPOSITION CONTAINING AT LEAST ONE INHIBITOR OF CERTAIN CHEMOATTRACTANT CYTOKINES | GREENPHARMA S A (FR) | 2021-03-31 | — | — | EP | disclosed |
| EP-3197458-B1 | DERMOCOSMETIC OR PHARMACEUTICAL USE OF A COMPOSITION CONTAINING AT LEAST ONE INHIBITOR OF CERTAIN CHEMOATTRACTANT CYTOKINES | GREENPHARMA S A (FR) | 2021-03-31 | — | — | EP | disclosed |
| US-10828309-B2 | Dermocosmetic or pharmaceutical use of a composition comprising at least one inhibitor of some chemoattractant cytokines | GREENPHARMA (FR) | 2020-11-10 | — | — | US | disclosed |
| US-10828309-B2 | Dermocosmetic or pharmaceutical use of a composition comprising at least one inhibitor of some chemoattractant cytokines | GREENPHARMA (FR) | 2020-11-10 | — | — | US | disclosed |
| US-20170296547-A1 | DERMOCOSMETIC OR PHARMACEUTICAL USE OF A COMPOSITION COMPRISING AT LEAST ONE INHIBITOR OF SOME CHEMOATTRACTANT CYTOKINES | UNIVERSITE DE STRASBOURG (FR) | 2017-10-19 | — | — | US | disclosed |
| US-20170296547-A1 | DERMOCOSMETIC OR PHARMACEUTICAL USE OF A COMPOSITION COMPRISING AT LEAST ONE INHIBITOR OF SOME CHEMOATTRACTANT CYTOKINES | UNIVERSITE DE STRASBOURG (FR) | 2017-10-19 | — | — | US | disclosed |
| US-20170296547-A1 | DERMOCOSMETIC OR PHARMACEUTICAL USE OF A COMPOSITION COMPRISING AT LEAST ONE INHIBITOR OF SOME CHEMOATTRACTANT CYTOKINES | UNIVERSITE DE STRASBOURG (FR) | 2017-10-19 | — | — | US | disclosed |
| WO-2016046457-A1 | DERMOCOSMETIC OR PHARMACEUTICAL USE OF A COMPOSITION CONTAINING AT LEAST ONE INHIBITOR OF CERTAIN CHEMOATTRACTANT CYTOKINES | GREENPHARMA (FR) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170296547-A1 | DERMOCOSMETIC OR PHARMACEUTICAL USE OF A COMPOSITION COMPRISING AT LEAST ONE INHIBITOR OF SOME CHEMOATTRACTANT CYTOKINES | CCL2, CCL11, CCL5 | LMNA 3426/4885SMN1; SMN2 3531/4885POLB 1907/4885 |
| US-10828309-B2 | Dermocosmetic or pharmaceutical use of a composition comprising at least one inhibitor of some chemoattractant cytokines | CCL2, CCL11, CCL5 | LMNA 3426/4885SMN1; SMN2 3531/4885POLB 1907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.